Anupam Rasayan India has launched a mandatory open offer to acquire a 26% stake in Bliss GVS Pharma at ₹299 per share. The process begins on July 28, 2026, and is set to conclude on August 10, 2026. Investors can participate by tendering their shares through the stipulated process, with final settlements expected by late August.
Detailed Coverage
Anupam Rasayan India Ltd has officially commenced its open offer to acquire up to 26% of the share capital of Bliss GVS Pharma Ltd. This acquisition, priced at ₹299 per share, represents a total investment of approximately ₹829 crore. The move follows regulatory requirements under the Securities and Exchange Board of India (SEBI) guidelines, as the acquirer seeks to increase its footprint in the pharmaceutical industry.
Offer Mechanics and Timeline
The offer is a joint effort by Anupam Rasayan and Mates Visa Consultancy Private Limited. Unlike some private acquisitions, this is an unconditional offer, meaning it is not dependent on a specific minimum number of shares being tendered. Shareholders who held Bliss GVS Pharma stock as of July 14, 2026, are eligible to participate. If the total number of shares tendered by the public exceeds the 26% limit set for this offer, the shares will be accepted on a proportionate basis.
The tendering window is scheduled to remain open from July 28, 2026, to August 10, 2026. Following the closure, the final processing of payments and the return of any unaccepted shares are slated for completion by August 24, 2026. While the current offer price is set at ₹299 per share, the acquirers have maintained the option to revise this price upward before the tender period concludes, provided they follow regulatory protocols.
Strategic Context and Sector Dynamics
Anupam Rasayan is primarily a specialty chemicals manufacturer that has been looking to diversify its business model. By acquiring a significant stake in Bliss GVS Pharma, which focuses on various pharmaceutical formulations, the company is attempting to move closer to the final consumer market. This shift is a departure from its traditional business of supplying intermediate chemicals to global players. Investors should consider that this move involves a substantial cash outflow of ₹829 crore, which may impact the company’s cash flow position or debt levels depending on how the acquisition is financed.
Furthermore, the pharmaceutical and chemical sectors are currently navigating challenges related to input costs and global demand fluctuations. While Anupam Rasayan aims to build a stronger business advantage through this vertical integration, the success of this strategy will depend on how effectively the two entities can integrate their operations and leverage each other's strengths. Potential risks for investors include the standard challenges associated with corporate integration and the execution risk involved in entering a new segment of the healthcare market.
For shareholders of Bliss GVS Pharma, the key monitorable will be the level of public participation in the offer and whether the management structure sees changes following the completion of the stake acquisition. Investors should track the final settlement date and any subsequent filings by the companies regarding the integration process or future business strategies.